Lv4
478 积分 2023-01-10 加入
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
2天前
已完结
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
2天前
已完结
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
2天前
已完结
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
2天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
3天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
4天前
已完结
Talquetamab: First Approval
8天前
已完结
Epcoritamab: First Approval
8天前
已完结
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial
8天前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
8天前
已完结
皖公网安备34019202002308
